Symetis
Symetis developed and commercialized a next-generation percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions. The company was headquartered in Ecublens (Switzerland) and was acquired by Boston Scientific (NYSE: BSX) in 2017.